Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2097 | 37300-21-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sulfated pentosyl polysaccharide with heparin-like properties.
|
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | O |
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 3 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 26, 1996 | FDA | JANSSEN PHARMS |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Maculopathy | 2577.83 | 21.04 | 363 | 3800 | 2143 | 90622141 |
| Dry age-related macular degeneration | 547.73 | 21.04 | 71 | 4092 | 185 | 90624099 |
| Retinal pigmentation | 163.63 | 21.04 | 22 | 4141 | 82 | 90624202 |
| Off label use | 142.49 | 21.04 | 210 | 3953 | 1102042 | 89522242 |
| Retinal dystrophy | 113.44 | 21.04 | 14 | 4149 | 20 | 90624264 |
| Retinopathy | 106.22 | 21.04 | 26 | 4137 | 3508 | 90620776 |
| Retinal degeneration | 93.60 | 21.04 | 19 | 4144 | 1090 | 90623194 |
| Cystitis interstitial | 90.76 | 21.04 | 20 | 4143 | 1704 | 90622580 |
| Colon dysplasia | 70.30 | 21.04 | 11 | 4152 | 137 | 90624147 |
| Eyelid exfoliation | 55.51 | 21.04 | 10 | 4153 | 302 | 90623982 |
| Macular degeneration | 54.35 | 21.04 | 29 | 4134 | 37941 | 90586343 |
| Retinal drusen | 44.08 | 21.04 | 6 | 4157 | 25 | 90624259 |
| Age-related macular degeneration | 41.39 | 21.04 | 9 | 4154 | 720 | 90623564 |
| Neovascular age-related macular degeneration | 40.00 | 21.04 | 8 | 4155 | 425 | 90623859 |
| Retinal toxicity | 35.41 | 21.04 | 9 | 4154 | 1413 | 90622871 |
| Tuberculin test positive | 30.86 | 21.04 | 10 | 4153 | 3715 | 90620569 |
| Bladder pain | 29.57 | 21.04 | 9 | 4154 | 2728 | 90621556 |
| Cholecystitis chronic | 24.59 | 21.04 | 11 | 4152 | 9815 | 90614469 |
| Allodynia | 23.14 | 21.04 | 6 | 4157 | 1018 | 90623266 |
| Cystoid macular oedema | 23.09 | 21.04 | 7 | 4156 | 2093 | 90622191 |
| Choroidal neovascularisation | 22.97 | 21.04 | 5 | 4158 | 402 | 90623882 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Thermophobia | 63.53 | 36.74 | 9 | 1780 | 59 | 42619487 |
| Adrenocorticotropic hormone deficiency | 52.19 | 36.74 | 12 | 1777 | 1358 | 42618188 |
| Maculopathy | 44.08 | 36.74 | 10 | 1779 | 1065 | 42618481 |
| Prostatic pain | 42.23 | 36.74 | 8 | 1781 | 351 | 42619195 |
| Appendicolith | 41.52 | 36.74 | 17 | 1772 | 13439 | 42606107 |
| Hypophosphataemia | 40.36 | 36.74 | 19 | 1770 | 20926 | 42598620 |
| Appendicitis | 37.58 | 36.74 | 18 | 1771 | 20595 | 42598951 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Maculopathy | 1422.66 | 19.99 | 221 | 4647 | 2806 | 110581625 |
| Dry age-related macular degeneration | 232.48 | 19.99 | 34 | 4834 | 272 | 110584159 |
| Retinal pigmentation | 122.93 | 19.99 | 17 | 4851 | 86 | 110584345 |
| Cystitis interstitial | 94.72 | 19.99 | 20 | 4848 | 1454 | 110582977 |
| Retinal degeneration | 81.16 | 19.99 | 18 | 4850 | 1648 | 110582783 |
| Retinopathy | 72.85 | 19.99 | 20 | 4848 | 4409 | 110580022 |
| Colon dysplasia | 66.85 | 19.99 | 12 | 4856 | 371 | 110584060 |
| Thermophobia | 63.09 | 19.99 | 9 | 4859 | 59 | 110584372 |
| Eyelid exfoliation | 55.77 | 19.99 | 10 | 4858 | 307 | 110584124 |
| Off label use | 52.23 | 19.99 | 164 | 4704 | 1500021 | 109084410 |
| Adrenocorticotropic hormone deficiency | 46.04 | 19.99 | 12 | 4856 | 2170 | 110582261 |
| Prostatic pain | 43.30 | 19.99 | 8 | 4860 | 291 | 110584140 |
| Anal ulcer | 42.91 | 19.99 | 11 | 4857 | 1865 | 110582566 |
| Retinal dystrophy | 42.81 | 19.99 | 6 | 4862 | 34 | 110584397 |
| Appendicolith | 39.74 | 19.99 | 17 | 4851 | 14238 | 110570193 |
| Appendicitis | 39.49 | 19.99 | 21 | 4847 | 28443 | 110555988 |
| Macular degeneration | 35.87 | 19.99 | 18 | 4850 | 21641 | 110562790 |
| Bacteroides infection | 33.68 | 19.99 | 10 | 4858 | 2909 | 110581522 |
| Myasthenia gravis | 33.07 | 19.99 | 17 | 4851 | 21494 | 110562937 |
| Tuberculin test positive | 31.43 | 19.99 | 10 | 4858 | 3658 | 110580773 |
| Libido decreased | 30.42 | 19.99 | 11 | 4857 | 5924 | 110578507 |
| Age-related macular degeneration | 28.72 | 19.99 | 7 | 4861 | 966 | 110583465 |
| Hypophosphataemia | 28.70 | 19.99 | 18 | 4850 | 33164 | 110551267 |
| Hyperphosphataemia | 28.26 | 19.99 | 14 | 4854 | 16367 | 110568064 |
| Hypopituitarism | 25.77 | 19.99 | 9 | 4859 | 4381 | 110580050 |
| Retinal toxicity | 25.02 | 19.99 | 7 | 4861 | 1652 | 110582779 |
| Gonadotrophin deficiency | 23.86 | 19.99 | 4 | 4864 | 82 | 110584349 |
| Hypogonadism | 23.75 | 19.99 | 7 | 4861 | 1987 | 110582444 |
| Ventricular fibrillation | 22.84 | 19.99 | 17 | 4851 | 41296 | 110543135 |
| Blood phosphorus increased | 22.51 | 19.99 | 12 | 4856 | 16328 | 110568103 |
| Ulcer | 22.19 | 19.99 | 17 | 4851 | 43099 | 110541332 |
| Cholecystitis chronic | 22.17 | 19.99 | 10 | 4858 | 9490 | 110574941 |
| Aortic stenosis | 22.05 | 19.99 | 11 | 4857 | 13048 | 110571383 |
| Total lung capacity decreased | 21.55 | 19.99 | 9 | 4859 | 7105 | 110577326 |
| Cystoid macular oedema | 21.40 | 19.99 | 7 | 4861 | 2793 | 110581638 |
| Analgesic therapy | 21.34 | 19.99 | 9 | 4859 | 7275 | 110577156 |
| Drug therapy | 21.33 | 19.99 | 9 | 4859 | 7282 | 110577149 |
| Sleep disorder therapy | 21.12 | 19.99 | 9 | 4859 | 7462 | 110576969 |
| Neuralgia | 20.44 | 19.99 | 17 | 4851 | 48461 | 110535970 |
| Hyperlipidaemia | 20.38 | 19.99 | 15 | 4853 | 35833 | 110548598 |
| Lung opacity | 20.23 | 19.99 | 10 | 4858 | 11642 | 110572789 |
None
| Source | Code | Description |
|---|---|---|
| ATC | C05BA04 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES ANTIVARICOSE THERAPY Heparins or heparinoids for topical use |
| ATC | G04BX15 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Other urologicals |
| FDA CS | M0009496 | Glycosaminoglycans |
| MeSH PA | D000925 | Anticoagulants |
| MeSH PA | D006401 | Hematologic Agents |
| FDA EPC | N0000175837 | Glycosaminoglycan |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bladder pain | indication | 15803009 | |
| Ulcerative cystitis | indication | 111409009 | DOID:13949 |
| Urinary Tract Irritation | indication | ||
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Heparin-induced thrombocytopenia | contraindication | 73397007 | |
| Hemophilia | contraindication | 90935002 | |
| Bleeding | contraindication | 131148009 | |
| Arterial aneurysm | contraindication | 233981004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Diverticulitis of gastrointestinal tract | contraindication | 271366000 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Surgical procedure | contraindication | 387713003 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| D05428 | KEGG_DRUG |
| 4021013 | VANDF |
| C0600296 | UMLSCUI |
| CHEMBL1201516 | ChEMBL_ID |
| D010426 | MESH_DESCRIPTOR_UI |
| DB00686 | DRUGBANK_ID |
| 140207-93-8 | SECONDARY_CAS_RN |
| F59P8B75R4 | UNII |
| 134413 | RXNORM |
| 5255 | MMSL |
| 5909 | MMSL |
| 80071 | MMSL |
| d04052 | MMSL |
| 004395 | NDDF |
| 109116008 | SNOMEDCT_US |
| 109117004 | SNOMEDCT_US |
| 372571007 | SNOMEDCT_US |
| CHEBI:749457 | CHEBI |
| 92043424 | PUBCHEM_CID |
| 6311 | INN_ID |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ELMIRON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-098 | CAPSULE, GELATIN COATED | 100 mg | ORAL | NDA | 25 sections |
| Elmiron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4525 | CAPSULE, GELATIN COATED | 100 mg | ORAL | NDA | 25 sections |